Immunic to Host R&D Day on November 5
The company will detail plans for a upcoming Phase 3 trial regarding progressive multiple sclerosis treatments.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Do you trust pharmaceutical companies to prioritize effective treatments for chronic progressive diseases?
Immunic will host a virtual Research and Development Day on November 5, 2026. The event serves as a platform to outline plans for a Phase 3 clinical trial of vidofludimus calcium for progressive multiple sclerosis.
Why it matters
This presentation aims to address significant unmet medical needs in progressive multiple sclerosis by highlighting the potential neuroprotective effects of the drug. Management intends to share the clinical and scientific rationale for the upcoming trial.
Immunic is preparing to launch a Phase 3 trial for vidofludimus calcium, a drug candidate that functions as a Nurr1 activator. This trial is expected to be initiated later in 2026.
The players
Erik Lundgren
He serves as the Chief Executive Officer at Immunic.
Michael Panzara
He is the Chief Medical Officer for the company.
Hella Kohlhof
She acts as the Chief Scientific Officer at Immunic.
Jason Tardio
He serves as the Chief Operating Officer of the firm.
Jiwon Oh
She is an expert speaker from the University of Toronto.
The details
Company leadership will join external experts to discuss the therapeutic potential of vidofludimus calcium. The virtual event will feature presentations from key scientific figures in the field of multiple sclerosis research.
Timeline
November 5, 2026: Immunic hosts its virtual Research and Development Day.
Late 2026: The company expects to initiate the Phase 3 clinical trial.
The Big Picture
This development follows the trajectory of the ongoing clinical development of Nurr1 activators for neurodegenerative disease. Immunic is positioning its lead candidate for critical Phase 3 testing to determine its efficacy against existing standards.
The upcoming trial results could potentially provide new treatment options for those living with progressive multiple sclerosis. Patients and caregivers should monitor trial progress as investigators continue to evaluate the potential neuroprotective benefits of this therapy.
The takeaway
Clinical trials are vital for determining whether new drugs can offer neuroprotective benefits for progressive conditions. Interested parties should watch for future updates on trial enrollment and outcomes as the company moves into the next phase of development.
What happens next
The company is scheduled to host the virtual R&D event on November 5, 2026, followed by the planned initiation of its Phase 3 clinical trial later in 2026.
Further reading
For more information on current neurodegenerative research, visit the Alzheimer’s section.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Do you trust pharmaceutical companies to prioritize effective treatments for chronic progressive diseases?
